Research Programs Discontinued
0
Drugs Discontinued
0
since passage of the Inflation Reduction Act
News Updates
Incubate’s Investment Tracker measures the impacts of the Inflation Reduction Act’s healthcare provisions on the life sciences ecosystem, with special attention to the impacts of the small molecule penalty.
Date
Disease Area
Drug Type
Announcement Type
Company Size
Search
January 5, 2026
Delnaggar Biotech Group
Orphan Drug Designation
FDA orphan drug designation: treatment of high-grade anal intraepithelial neoplasia (HGAIN)
Disease Area: Rare Diseases
January 5, 2026
Nanjing RegeneCore Biotech Co.
Orphan Drug Designation
FDA orphan drug designation: treatment of acute myeloid leukemia
Disease Area: Rare Diseases
January 1, 2026
mAbTree Biologics AG
Orphan Drug Designation
FDA orphan drug designation: treatment of essential thrombocythemia
Disease Area: Rare Diseases
December 31, 2025
Pharmascience Inc.
Orphan Drug Designation
FDA orphan drug designation: treatment of pericarditis
Disease Area: Rare Diseases
December 31, 2025
Haichang Biotech Co.
Orphan Drug Designation
FDA orphan drug designation: treatment of osteosarcoma
Disease Area: Rare Diseases
December 23, 2025
Veloxis Pharmaceuticals
Orphan Drug Designation
FDA orphan drug designation: prevention of organ rejection in patients receiving a liver transplant
Disease Area: Rare Diseases
December 19, 2025
HemaCell Biotechnology Inc.
Orphan Drug Designation
FDA orphan drug designation: treatment of Bernard-Soulier syndrome
Disease Area: Rare Diseases
December 19, 2025
Novita Pharmaceuticals
Orphan Drug Designation
FDA orphan drug designation: treatment of pancreatic cancer
Disease Area: Rare Diseases
December 19, 2025
Academic Pharmaceuticals Inc.
Orphan Drug Designation
FDA orphan drug designation: treatment of Kawasaki disease
Disease Area: Rare Diseases
December 19, 2025
Novartis Pharmaceuticals Corporation
Orphan Drug Designation
FDA orphan drug designation: treatment of myasthenia gravis
Disease Area: Rare Diseases